亚洲人群的甲状腺眼病状况及其诊治进展

Thyroid eye disease in Asians and recent advances in management

本文旨在回顾当前对甲状腺眼病(TED)的认识和研究进展,侧重于亚洲人群的相关资料。TED可以显著影响患者的生活质量,并且带来诸如容貌损毁和失明等严重后果。近期研究发现,替妥木单抗(teprotumumab),一种可抑制胰岛素样生长因子1受体(IGF-1R)的人源单克隆抗体,已成为TED的新兴靶向治疗方案。该药可逆转活动性中重度TED的疾病进程。随机临床试验表明,与安慰剂相比,替妥木单抗可显著改善患者的临床活动性评分、眼球突出度、主观性复视和随访4个月后的生活质量。本文将综述TED的流行病学、病理生理学及其诊治方面的最新进展。

This paper aims to review the current understanding and advances in knowledge of thyroid eye disease(TED)with a focus on Asian population.TED can significantly impact quality of life,and has devastating consequences,including facial disfigurement and vision loss.Recent findings revealed a novel targeted therapy against TED,including teprotumumab,a human monoclonal antibody that inhibits the insulin-like growth factor-1 receptor.Teprotumumab was found to reverse the disease process in patients with active,moderate-to-severe TED.A randomized clinical trial of this drug compared to placebo showed significant improvement in clinical activity score,proptosis,subjective diplopia,and quality of life at 4 months follow-up in the treatment group.In this paper,we review the current epidemiology,pathophysiology,and advances in management of TED.